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Available online 01 November 2016This study describes the NMR-based method to determine the limit of quantitation (LOQ) and limit of detection
(LOD) of cholesterol, a process-related impurity in the replication-deﬁcient Herpes Simplex Virus (HSV) type 2
candidate vaccine HSV529. Three signature peaks from the 1D 1H NMR of a cholesterol reference spectrum
were selected for the identiﬁcation of cholesterol. The LOQ for a cholesterol working standard was found to be
1 μg/mL, and the LOD was found to be 0.1 μg/mL. The identity of cholesterol, separated from the formulation of
growth supplement by thin layer chromatography (TLC), was conﬁrmed by 1D 1H NMR and 2D 1H-13C HSQC
NMR. The three signature peaks of cholesterol were detected only in a six-times concentrated sample of
HSV529 candidate vaccine sample and not in the single dose HSV529 vaccine sample under similar experimental
conditions. Taken together, the results demonstrated that NMR is a direct method that can successfully identify
and quantify cholesterol in viral vaccine samples, such as HSV529, and as well as in the growth supplement used
during the upstream stages of HSV529 manufacturing.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural
Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.
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HSV529 is a replication deﬁcient viral vaccine candidate (d15–29)
against genital herpes caused by theHerpes Simplex Virus type-2 strain.
It is engineered by deleting two early protein genes – UL5 and UL29 –
which renders it incapable of viral DNA replication [1]. To date,
HSV529 has been proven safe, effective and shows promising immuno-
genicity in animal models [1]. Currently, this viral vaccine candidate is
being tested in a clinical in Phase I study [2–4].
Vaccine development, like any drug development, is a long and
rigorous process to ensure the safety of the end user. Multiple testing,
such as monitoring process-related impurities, is required to ensure
the integrity of the ﬁnal product.
To assess impurities, a list of all materials used in the manufacturing
of HSV529 was compiled along with their estimated concentrations in
the ﬁnal HSV529 Drug Product. These estimations were calculated
using the “worst case” scenarios, e.g. by assuming no removal of
components during the processing. The growth supplement, as one of
the components used, is an additive required for the growth of the
cells used in the upstream fermentation. It was estimated to be present
at a concentration of 5.3 μg/dose, where each dose is 0.5 mL.(M. Kirkitadze).
. on behalf of Research Network of CCholesterol is one of the components in the growth supplement. Al-
though there is no toxicological assessment available for cholesterol,
the acceptablemaximum cholesterol level set for this vaccine candidate
is 3 μg/mL (1.5 μg/dose). This limit was calculated using the FDA
Guidance for Industry “Genotoxic and Carcinogenic Impurities in Drug
Substances and Products: Recommended Approaches” (2008) [5] and
the EMA/CHMP/QWP/251,344/2006 guideline [6]. Both guidelines con-
sider an acceptable maximum of 1.5 μg/dose for genotoxic impurities
lacking toxicological assessments.While there is no indication that cho-
lesterol is genotoxic or carcinogenic, this level is used as an initial target
for the purpose of deﬁning desirable limits of detection and of
quantiﬁcation.
Plausible analytical methods to assess the cholesterol content
include gas–liquid chromatography or liquid chromatography, coupled
with ﬂame ionization or mass spectrometry detection [7–9], and
ﬂuorometric [12] or colorimetric enzymatic assays [10,11]. The chroma-
tography and mass spectrometry methods are relatively time consum-
ing and require chemical saponiﬁcation of cholesterol esters. The
colorimetric and ﬂuorometric enzymatic methods, on the other hand,
are simple, sensitive, and relatively faster assays that can measure the
total cholesterol content, and cholesterol mass in cholesterol esters
[13]. However, the aim was to determine the residual cholesterol con-
tent remaining from the growth supplement without further modiﬁca-
tion, i.e. without the esteriﬁcation of cholesterol. Therefore, Nuclearomputational and Structural Biotechnology. This is an open access article under the CC BY
Fig. 1. Determination of scan numbers required for LOQ and LOD of cholesterol in CDCl3
using 1D 1H NMR. The spectra show the 1H chemical shifts of cholesterol at 10 μg/mL
(panel A, 8 scans) 1 μg/mL (panel B, 512 scans) and 2500 μg/mL (panel C, 8 scans).
Three non-overlapping, signature peaks are indicated as asterisk (*), triangle (▲) and
rectangle (◘) at 5.38, 3.55 and 0.7 ppm, respectively, that have unique chemical shifts
for cholesterol. Closed circle (●) indicates the peak for chloroform at 7.5–7.0 ppm. Panel
D shows the cholesterol structure with the unique protons identiﬁed.
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of choice as it can analyze the lyophilized vaccine reconstituted in
chloroform without further sample treatment.
NMR is routinely used in academia for the study of biomolecules.
This method has been proven to be an important tool to characterize
newly synthesized peptides, polymers, natural compounds and
metabolites [14–16]. Recent studies demonstrated that NMR can be
used routinely for the reliable quantiﬁcation of small molecules to
assess the product's purity [14,20,21,23,24]. It has been used to identify
and quantify polysaccharides in protein conjugate vaccines such as Hib
and meningococcal capsular polysaccharides [17–19]. NMR utilizes
various techniques based on the particular nucleus under study,
e.g., proton-proton, proton-carbon, and proton-nitrogen. Quantitative
information is extracted from the signal integrals – resonance lines
that do not overlap with other resonances – that are linearly propor-
tional to the concentration of the analyte. Conventionally, a reference
substance of known concentration is run along the sample to calculate
the concentration of the different constituents [14].
Previously, an attempt was made to detect cholesterol in aqueous
solutions of the HSV529 candidate vaccine and the growth supplement
using NMR; however, it was not successful (data not shown). To further
assess theNMRmethod in evaluating cholesterol levels, cholesterolwas
extracted from the HSV529 candidate vaccine and growth supplement
using chloroform prior NMR analysis.
Since there are no internal standards for cholesterol, the Limit of
Quantiﬁcation (LOQ) and Limit of Detection (LOD) of cholesterol
were ﬁrst determined using a reference standard (Caledon Laborato-
ries Ltd). These limits were then used to assess the presence of cho-
lesterol in the growth supplement and in the HSV529 candidate
vaccine. In summary, the objectives of this study were to develop
NMR methods to: (a) identify and quantify cholesterol as a
process-related impurity in HSV529, and (b) assess the presence of
cholesterol in the growth supplement. The samples analyzed in this
study include the cholesterol standard, the growth supplement and
the HSV529 vaccine candidate.
2. Materials and Methods
2.1. Key Data Acquisition Parameters
A Bruker AVANCE 700MHz Nuclear Magnetic Resonance Spectrom-
eter equipped with a 5 mm cryoprobe and a Z-axis pulse ﬁeld gradient
was used throughout this study. The key acquisition parameters for 1D
1H NMR protein antigen sample spectra were as follows: eight and 512
scans, a relaxation delay of ﬁve seconds, 90° pulsewidth of 8 μsec at a
transmitter power of 7.59 W, temperature of 25 °C, acquisition time of
2.32 s, and spectral width (swh) 14,097.7 Hz with 64 K acquired data
points. The FID signal was locked using the CDCl3 solvent and then op-
timized formagneticﬁeld homogeneity (shimmed). The90° pulsewidth
was calibrated prior to the experiment.
2.2. LOQ/LOD for Cholesterol Powder
To determine the optimum scan number, cholesterol powder
(Caledon Laboratory Chemicals) was dissolved in CDCl3 (99.8%, Sigma-
Aldrich) and loaded into an NMR tube in concentrations of 10, 1 and
2500 μg/mL, respectively. 1D 1H NMR spectra were collected at 8 versus
512 scans in 300 μl volume using 3 mm NMR tube as described in
Section 2.1. For LOQ and LOD, 1D 1H NMR spectra were obtained for a
series of cholesterol dilutions in CDCl3 at 100, 10, 1 and 0.1 μg/mL,
respectively. For each dilution, 512 scanswere collected in the same ex-
perimental conditions. Both experiments were repeated using 5 mm
NMR tube and the spectra were processed using NMR software
TOPSPIN version 3.1 and compared with the 1D 1H NMR spectrum of
cholesterol in CDCl3 [22].2.3. Detection of Cholesterol in Growth Supplement
According to the supplier's product description, the growth supple-
ment is an aqueous cholesterol solution in a proprietary formulation.
As shown in Supplement 1 (Fig. S1), previous 1D 1H NMR experiments
suggested the presence of unknown components in the growth supple-
ment solution that overlapped with cholesterol's signals [2]. In an at-
tempt to separate cholesterol from the other components in the
growth supplement solution, a thin layer chromatography (TLC) meth-
od [21] was employed prior to 1D 1H NMR measurement.
TLC is a separation technique for non-volatile compounds, and is
performed on a sheet of glass, plastic, or aluminum foil that is coated
with a thin layer of adsorbent material. In this study, a TLC plate was
used with silica gel as stationary phase. 5 μl of growth supplement
and reference cholesterol samples (2500 μg/mL in CDCl3, Caledon
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tom of the plate (Fig. 3). The platewas then eluted at room temperature
using a benzene-d6:ethyl acetate:glacial acetic acid (Sigma Aldrich)
mixture in a 60:40:1 ratio. After elution, the plate was covered with a
ceric ammonium molybdate solution (Sigma Aldrich) and heated. The
ceric ammonium nitrate (Sigma Aldrich) was only used on a test plate
to measure the retention index. This retention index was measured on
a preparative plate and the region containing cholesterol was collected
(see Fig. 3) and dissolved in 300 μl CDCl3 to make the NMR sample.
Therefore, ceric ammonium nitrate did not come in contact with the
cholesterol used for NMR analysis. 1D 1H and 2D 1H-13C NMR data
(512 scans) were collected as described in Section 2.1 and spectra
were processed using TOPSPIN software version 3.1.2.4. Detection and Quantitation of Cholesterol in HSV529
To detect residual cholesterol in the candidate vaccine, two separate
cholesterol extractionswere performed. Since cholesterol is insoluble in
water (critical micellar concentration of 1.3–6.5 X 10−8M [25]), chloro-
form solvent extractionmethodwas chosen to isolate cholesterol. In the
ﬁrst extraction experiment, 0.5 mL of 99.8% CDCl3 was added to each
vial (0.5 mL) of lyophilized HSV529 therapeutic vaccine. Samples were
sonicated for 10 min in a water bath and the clear chloroform solution
was collected into two samples: (a) single dose sample and (b) 6X con-
centrated sample. CDCl3 was evaporated using a rotary evaporator and
the pooled sample was re-dissolved in 500 μl of 99.8% CDCl3 priorBA
1H (proton) chemica
Fig. 2. 1D 1H NMR spectra of cholesterol in CDCl3 at four different dilutions. Spectra are stacke
(bottom) μg/mL, respectively. 512 scans for each dilution are used and shown as offset to the
are indicated as asterisk (*, panel A), triangle (▲, panel B) and rectangle (◘, panel C) at 5.38,
Closed circle (●) indicates the peak for chloroform at 7.5–7.0 ppm that is used as internal refecollecting the 1D 1H NMR. Data were collected in three replicates and
2D 1H-13C NMR and cholesterol spiking were performed for six-times
concentrated sample only as the 1D 1H NMR data did not identify
cholesterol in a single dose (0.5 mL sample). Finally, the spectra were
processed and analyzed.
The amount of cholesterol present in two of the three aliquots from
the previous section was determined by spiking with the standard cho-
lesterol. Using a 10 μg/mL solution of cholesterol in CDCl3, a 50 μL spike
was added to each of two aliquots and the spectra were recorded using
identical conditions and parameters used in the previous experiment.
After processing the spectra similarly to the original spectra (i.e. 1 zero
ﬁll, 0.3 Hz line broadening and standard polynomial baseline correction),
the original and the spiked spectrawere scaled relative to each other and
compared to calculate the difference in the peak heights. The cholesterol
concentrations were determined using the following relationship:
Cx
Cxþ Cs ¼
SignalðxÞ
Signalðxþ sÞ ;
where:
Cx unknown concentration.
Cs concentration of the standard in the spiked solution (i.e.
10 μg/mL x (50 μL ÷ 550 μL) = 0.91 μg/mL).
Signal(x) original resonance intensity (set to 1 in each case).
Signal(x + s) resonance intensity after addition of the cholesterol
spike.C
l shift at ppm
d from top to bottom at the following order: 0.1 (top), 1 (2nd top), 10 (3rd top) and 100
right of the axis (bottom to top). Three non-overlapping signature peaks for cholesterol
3.55 and 0.7 ppm, respectively. These peaks have unique chemical shifts for cholesterol.
rence to show the scale.
Growth
Supplement
Reference 
Cholesterol
Cholesterol
TL
C
Fig. 3. TLC extraction of cholesterol from growth supplement. 5 μL of each sample was
inserted into the corresponding slots at the bottom of the plate as indicated. After
development, cholesterol for growth supplement were scrapped off and dissolved in
CDCl3 for NMR experiment.
1H (proton) che
B
A
Fig. 4. 1D 1H NMR identiﬁed cholesterol in growth supplement sample after preparative TLC is
panel B represents the reference cholesterol spectrum. Three non-overlapping, signature peak
respectively, that have unique chemical shifts for cholesterol. Closed circle (●) indicates the pe
(5.38 ppm, *)
(3.55 ppm,
(0.7 ppm,
1H (proton) chemical shift at ppm
13C (carbon) chem
ical shift at ppm
Fig. 5. 2D 1H-13C NMR detected cholesterol signature peaks in TLC isolated cholesterol
from growth supplement sample. 2D 1H-13C NMR spectra for cholesterol of growth
supplement (blue spots) and reference cholesterol (red spots) are aligned.
Superimposed three signature peaks at 5.38, 3.55 and 0.7 ppm are shown within square
boxes where 1H-13C cross peaks were identiﬁed for both samples. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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3.1. LOQ of Cholesterol Is 1 μg/mL and LOD of Cholesterol Is 0.1 μg/mL
Previously, assessment of the presence of residual growth
supplement or the cholesterol for the HSV529 vaccine candidate was
performed in aqueous solutions. The 1D 1H NMR spectra of the growthmical shift at ppm
olation. Panel A represents the spectrum of cholesterol isolated from growth supplement,
s are indicated as asterisk (*), triangle (▲) and rectangle (◘) at 5.38, 3.55 and 0.7 ppm,
ak for chloroform at 7.5–7.0 ppm.
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cholesterol in either sample. The 1D 1H NMR spectrum of the growth
supplement showed no characteristic signature peaks of cholesterol.
Furthermore, HSV529 vaccine candidate in aqueous solution spectrum
showed no presence of the growth supplement.
These observations led to changes in the sample preparation
methods for the growth supplement and the HSV529 vaccine, which
in turn allowed the measurement of residual cholesterol at the
microgram level by NMR. The LOQ and LOD of cholesterol by NMR
were determined ﬁrst.
The 1D 1H NMR spectrum of cholesterol indicates many aliphatic
proton resonances in the chemical shift ranges of 2.4–0.6 ppm, as well
as unique resonances at 5.38, 3.55 and 0.70 ppm (Fig. 1 panels A-C).
The unique resonances at 5.38, 3.55 and 0.70 ppmwere assigned to cho-
lesterol, since there was very little, if any, spectral overlap from other
compounds in these chemical shift regions [22,26]. To determine the
optimal number of scans required for quantitation of cholesterol, data
were collected at 8 versus 512 scans at different concentrations. As
shown in Fig. 1 (panel A), the 8-scan spectra of cholesterol showed sig-
nature peaks at 5.38, 3.55 and 0.70 ppm (chemical shift and peak area)
for the 10 μg/mL of cholesterol. Furthermore, using 512 scans, signature
peaks were detected at the concentration as low as 0.1 μg/mL of choles-
terol indicating that the signature peaks of cholesterol are detectable at
microgram level as shown in Fig. 1 panel B. Fig. 1 panel C shows that a
higher cholesterol concentration (2500 μg/mL, 8 scans) was used as a
positive control.1H (proton) chemi
C
B
A
Fig. 6. 1D 1H NMR detected cholesterol in concentrated HSV529 vaccine sample. Panel A and
samples, respectively. Panel C shows the LOQ spectrum of reference cholesterol (1 μg/mL o
representative spectrum for 6 times concentrated HSV529 vaccine. Three non-overlapping, si
0.7 ppm, respectively, that have unique chemical shifts for cholesterol. Closed circle (●) indicaNext, to determine the LOQ and LOD, a series of dilutions of choles-
terol by factor of 10 were analyzed by 1D 1H NMR. As shown in Fig. 2,
cholesterol signals were decreased as a result of dilution from
100 μg/mL to 1 μg/mL. All three signature peaks were still visible and
quantiﬁable at 1 μg/mL; therefore, the LOQ of cholesterol was found to
be 1 μg/mL. At the concentration of 0.1 μg/mL only two signature
peaks of 5.38 and 0.7 ppm were clearly visible; whereas, the peak at
3.55 ppm is missing. Therefore, LOD is claimed to be 0.1 μg/mL. Al-
though it would be preferable to have all three signature peaks for
LOD, from safety point of view, it is important to consider the HSV529
sample where at least one peak of cholesterol is detectable.
3.2. 1D/2D NMR Is Useful to Detect Cholesterol in Growth Supplement
Sample at LOD Level
Previous 1D 1H NMR experiments suggested the presence of
additional unknown components in the formulation of the growth
supplement with signals overlapping with the cholesterol signals
[22]. To examine growth supplement, cholesterol was isolated from
the proprietary formulation using TLC. As shown in Fig. 3, the reten-
tion time for the spot from the growth supplement was the same as
cholesterol standard, indicating that cholesterol was separated
from growth supplement. Fig. 4 shows the 1D 1H NMR showed
cholesterol spectrum with three signature peaks. Furthermore, 2D
1H-13C HSQC conﬁrmed the presence of cholesterol in the growth
supplement. (See Fig. 5.)cal shift at ppm
B represent spectrum for 0.5 mL (single dose), and 6 times concentrated HSV529 vaccine
f cholesterol). Panel A shows the representative spectrum for 0.5 mL and Panel B is the
gnature peaks are shown as asterisk (*), triangle (▲) and rectangle (◘) at 5.38, 3.55 and
tes the peak for satellite cholesterol from chloroform at 7.5–7.0 ppm.
1H (proton) chemical shift at ppm
13C (carbon) chem
ical shift at ppm
(5.38 ppm, *)
(3.55 ppm,
Fig. 7. 2D 1H 13C NMR detected cholesterol signature peaks in 6 times concentrated
HSV529 sample: 2D 1H-13C NMR spectra for cholesterol of HSV529 (red spots) and
reference cholesterol (blue spots) are aligned. Superimposed three signature peaks at
5.38, 3.55 and 0.7 ppm are shown within square boxes where 1H-13C cross peaks were
identiﬁed for both samples. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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Sample in Microgram Level
Our previous experiments did not detect cholesterol in HSV529 vac-
cine sample in aqueous solution, possibly due to the fact that: (a) cho-
lesterol is insoluble in water (critical micellar concentration of 1.3–6.5
X 10–8 M [25]), and (b) larger vaccine components mask the smaller
cholesterol molecule. Therefore, to detect and quantitate the residual
cholesterol in HSV529 vaccine, cholesterol was extracted in chloroform
and examined by 1D/2D NMR. As shown in Fig. 6 panel A, for the single
dose of HSV529, the baseline of the spectrum became far wider and
none of the three signature peaks were identiﬁed. In contrast, as
shown in Fig. 6 panel B all three signature peaks were identiﬁed based
on LOQ of reference cholesterol. Furthermore, cross-peaks between
proton-carbon for the three peaks were conﬁrmed using 2D 1H-13C
HSQC as shown in Fig. 7. Table 1 shows the cholesterol concentration
in two concentrated vaccine samples through spiking with reference
cholesterol as described and in Section 2.4. The amount of cholesterol
were found to be in the range of 1.08 μg/mL - 1.92 μg/mL, calculated
using the formula described in Section 2.4 which was near to the LOQ
of 1 μg/mL of cholesterol standard. Taken together, NMRmethodologies
employed in this study has proven to be useful to study cholesterol in
complex biological molecules, like HSV529 vaccine.4. Conclusion and Recommendations
1H NMR is a well-established method to identify and characterize
small chemicals in the pharmaceutical industry [23,24]. In this study,
NMR spectroscopy was evaluated for the identiﬁcation andTable 1
Determination of cholesterol concentration in concentrated HSV529 samples.
Sample #
Resonance
Shift (δ ppm)
Signal(x+s) (relative to
the original intensity of 1 unit)
Corrected1
Concentration
(μg/mL)
1 0.70 1.92 1.08
1 5.37 1.52 1.92
2 0.70 1.74 1.34
2 5.37 1.69 1.44
1. The concentrations of the samples were adjusted to account for a loss of resonance in-
tensity caused by dilution from 500 μl to 550 μl.quantiﬁcation of a process-related impurity in vaccine candidate. The
immediate goal was to develop a method to monitor cholesterol levels
in HSV529 vaccine samples. The developed 1D 1H NMR and 2D 1H-13C
NMR methods were shown to be suitable for the quantiﬁcation and
identiﬁcation of cholesterol in HSV529 samples.
Initially, the LOD and LOQwere determined using a commercial cho-
lesterol sample, which also served as a standard. The LOQ and the LOD
measured by the 1D 1H NMR method developed were estimated at
1.0 μg/mL and 0.1 μg/mL, respectively. The LOQ was determined using
a series of dilutions of a cholesterol standard. The LOD was determined
by further dilutions and based on the three signature peaks of the refer-
ence cholesterol spectrum [22].
Based on the LOD/LOQ, cholesterol was detected in HSV529 samples
concentrated six times. This result was further conﬁrmed using 2D
1H-13C NMRmethods. The cholesterol concentrations in the concentrat-
edHSV529 sampleswere varied from1.08 to 1.92 μg/mL. However, cho-
lesterol levels measured in non-concentrated samples of HSV529 were
below the LOD, which is likely due to a masking effect. HSV viral parti-
cles, host cell proteins, andmost likely a biological stabilizer added dur-
ing the process can be responsible for matrix effect. To mitigate the
matrix effect that is masking cholesterol, HSV529 ﬁnal ﬁlled Drug Prod-
uct will be analyzed.
The 1D 1HNMR and 2D 1H-13CHSQC spectra conﬁrmed the presence
of cholesterol in a fraction of the growth supplement samples extracted
using a TLC method. Routine NMR spectrometers without cryoprobe
can be also used for the detection and quantitation of cholesterol. How-
ever, to generate a comparable spectrum, a longer acquisition time and
greater number scans will be required.
In conclusion, the results of this study demonstrated that the NMR
method can successfully identify and quantify cholesterol in the
HSV529 vaccine candidate and in growth supplement used during the
upstream stages of vaccine manufacturing.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.csbj.2016.10.007.
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Executive Summary
Background
• This study describes the NMR spectroscopy method to determine the
limit of quantitation (LOQ) and limit of detection (LOD) of cholesterol,
a process-related impurity in the replication-deﬁcientHerpes Simplex
Virus (HSV) type 2, HSV529, candidate vaccine samples.
Method development study design
• Three signature peaks from the 1D 1H NMR of a cholesterol reference
spectrum selected for the identiﬁcation of cholesterol were used to
measure the LOQ and LOD, to identity of cholesterol separated from
the formulation of growth supplement, and to detect it in six-times
concentrated sample of HSV529 candidate vaccine.
Results and discussion
• The LOQ for a cholesterol working standard was found to be 1 μg/mL,
and the LOD was found to be 0.1 μg/mL. The identity of cholesterol
separated from the formulation of growth supplement by TLC was
20 R. Khatun et al. / Computational and Structural Biotechnology Journal 15 (2017) 14–20conﬁrmed by 1D 1H NMR and 2D 1H-13C HSQC NMR. Three signature
peaks of cholesterol were detected only in a six-times (3mL) concen-
trated sample of HSV529 candidate vaccine sample, however, they
were not found in the HSV529 vaccine sample (0.5 mL sample
volume).
Conclusions & recommendations
• The results demonstrated that NMR is a direct method that can suc-
cessfully identify and quantify cholesterol in viral vaccine samples,
such as HSV529, and aswell as in the growth supplement used during
the upstream stages of HSV529 manufacturing. The method can be
applied to examine the impact of the eventual process scale-up and
formulation on cholesterol level in of HSV529 candidate vaccine.
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